The U.S. Food and Drug Administration granted on Tuesday Fast Track designation to Johnson & Johnson’s JNJ investigational nipocalimab for moderate-to-severe Sjögren’s disease (SjD). Last year, FDA granted Breakthrough Therapy designation (BTD) for the …

Pharmaceutical giants Johnson & Johnson and Sanofi have stopped a late-stage clinical trial for their experimental E.coli vaccine after results failed to demonstrate sufficient efficacy. The companies announced on Thursday that while the vaccine showed …

Johnson and Johnson (J&J) has … vaccine for extraintestinal pathogenic Escherichia coli (E. Coli) after results were found … from the US market. E. Coli typically manifests as food … bacteriophages to treat uropathogenic E. Coli infections to the South …

… sufficiently effective at preventing E. coli disease (IED) compared … event caused by E. coli, and E. coli-related pyelonephritis and … on extraintestinal pathogenic E. coli vaccine phase 3 clinical … /johnson-johnson-statement-on-phase-3-e-mbrace-study …

A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s vaccine candidate for extraintestinal pathogenic E. …

An independent data monitoring committee (IDMC) determined that the Sanofi and Johnson & Johnson’s vaccine candidate for extraintestinal pathogenic E coli was not sufficiently effective at preventing invasive E coli disease (IED) compared to placebo. …

Dive Brief: Sanofi and Johnson & Johnson are ending a Phase 3 study of an experimental E. coli vaccine after it failed to show a significant benefit over placebo in a review by an independent monitoring board. J&J began the study in 2021 and …

(Vax-Before-Travel)According to disappointing news released today, the world must wait for an approved vaccine that prevents invasive E. coli disease (IED). Sanofi announced today that a scheduled review of the E.mbrace phase 3 clinical study conducted by …

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial. In a statement issued this morning, the partners confirmed …

Sanofi and Johnson & Johnson on Thursday terminated the Phase III E.mbrace study of their investigational vaccine for invasive E. coli disease due to disappointing data. As a result of the termination, Sanofi will record a $250 million impairment …